Compare Organon & Co. Common Stock (OGN) vs Procter & Gamble Co (PG) Price & Performance

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.

Procter & Gamble (PG) trades at $153.05, showing modest daily movement with a slight 0.1% decline. The stock maintains strong technical momentum with bullish moving averages and key support at $152. Fundamentally, PG demonstrates robust profitability with 18.44% net margins and consistent earnings beats, though valuation multiples remain elevated versus peers. Recent corporate developments include dividend declarations and a new WNBA partnership, while analyst sentiment leans positive with a $160.13 consensus target.

PG offers stable dividend income with 69 consecutive years of increases, supported by strong cash flow generation. However, premium valuation and modest revenue growth create near-term headwinds. The stock presents a defensive play amid market volatility, but investors should monitor margin pressures and competitive dynamics in consumer staples. Upside potential exists if the company maintains earnings momentum above expectations.